Welcure Drugs [WELCURE] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison
Welcure Drugs
BSE
Loading...
Gujarat Themis
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Welcure Drugs wins in 7 metrics, Gujarat Themis wins in 12 metrics, with 0 ties. Gujarat Themis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Welcure Drugs | Gujarat Themis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 4.43 | 96.89 | Welcure Drugs |
| Price-to-Book Ratio | 0.89 | 17.39 | Welcure Drugs |
| Debt-to-Equity Ratio | 120.18 | 12.27 | Gujarat Themis |
| PEG Ratio | 0.00 | -3.07 | Gujarat Themis |
| EV/EBITDA | 7.51 | 65.59 | Welcure Drugs |
| Profit Margin (TTM) | 7.96% | 30.17% | Gujarat Themis |
| Operating Margin (TTM) | 10.38% | 33.14% | Gujarat Themis |
| EBITDA Margin (TTM) | 10.38% | 33.14% | Gujarat Themis |
| Return on Equity | 2.12% | 19.64% | Gujarat Themis |
| Return on Assets (TTM) | 0.81% | 16.19% | Gujarat Themis |
| Free Cash Flow (TTM) | $-2.22B | $-251.22M | Gujarat Themis |
| 1-Year Return | 62.62% | 83.00% | Gujarat Themis |
| Price-to-Sales Ratio (TTM) | 0.41 | 29.28 | Welcure Drugs |
| Enterprise Value | $2.57B | $42.26B | Gujarat Themis |
| EV/Revenue Ratio | 0.79 | 28.58 | Welcure Drugs |
| Gross Profit Margin (TTM) | 10.40% | 77.71% | Gujarat Themis |
| Revenue per Share (TTM) | $38 | $14 | Welcure Drugs |
| Earnings per Share (Diluted) | $2.69 | $4.09 | Gujarat Themis |
| Beta (Stock Volatility) | -1.76 | -0.40 | Welcure Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Welcure Drugs vs Gujarat Themis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Welcure Drugs | -4.94% | 0.68% | 19.32% | 11.19% | 72.25% | 7.48% |
| Gujarat Themis | 1.09% | 10.88% | 7.56% | 26.97% | 64.54% | 64.54% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Welcure Drugs | 62.62% | 50.13% | 496.00% | 354.96% | 254.76% | -12.09% |
| Gujarat Themis | 83.00% | 83.00% | 83.00% | 83.00% | 83.00% | 83.00% |
Performance & Financial Health Analysis: Welcure Drugs vs Gujarat Themis
| Metric | WELCURE | GUJTHEM |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.34B | ₹43.28B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 7,522,990 | 137,612 |
| 90 Day Avg. Volume | 3,381,856 | 213,338 |
| Last Close | ₹11.92 | ₹400.60 |
| 52 Week Range | ₹6.40 - ₹15.89 | ₹208.00 - ₹405.00 |
| % from 52W High | -24.98% | -1.09% |
| All-Time High | ₹25.00 (Sep 19, 2005) | ₹405.00 (Aug 01, 2025) |
| % from All-Time High | -52.32% | -1.09% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -34.93% | -0.08% |
| Quarterly Earnings Growth | N/A | -0.32% |
| Financial Health | ||
| Profit Margin (TTM) | 0.08% | 0.30% |
| Operating Margin (TTM) | 0.10% | 0.33% |
| Return on Equity (TTM) | 0.02% | 0.20% |
| Debt to Equity (MRQ) | 120.18 | 12.27 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹13.32 | ₹22.80 |
| Cash per Share (MRQ) | ₹0.01 | ₹1.15 |
| Operating Cash Flow (TTM) | ₹-2,249,340,000 | ₹969.95M |
| Levered Free Cash Flow (TTM) | ₹21.70M | ₹487.72M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Welcure Drugs vs Gujarat Themis
| Metric | WELCURE | GUJTHEM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 4.43 | 96.89 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.00 | -3.07 |
| Price to Sales (TTM) | 0.41 | 29.28 |
| Price to Book (MRQ) | 0.89 | 17.39 |
| Market Capitalization | ||
| Market Capitalization | ₹1.34B | ₹43.28B |
| Enterprise Value | ₹2.57B | ₹42.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.79 | 28.58 |
| Enterprise to EBITDA | 7.51 | 65.59 |
| Risk & Other Metrics | ||
| Beta | -1.76 | -0.40 |
| Book Value per Share (MRQ) | ₹13.32 | ₹22.80 |
Financial Statements Comparison: Welcure Drugs vs Gujarat Themis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | WELCURE | GUJTHEM |
|---|---|---|
| Revenue/Sales | ₹3.00B | ₹377.36M |
| Cost of Goods Sold | ₹2.69B | ₹83.50M |
| Gross Profit | ₹311.96M | ₹293.86M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹311.36M | ₹148.11M |
| EBITDA | ₹311.41M | ₹173.87M |
| Pre-Tax Income | ₹311.36M | ₹160.87M |
| Income Tax | ₹78.37M | ₹40.89M |
| Net Income (Profit) | ₹232.99M | ₹119.98M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | WELCURE | GUJTHEM |
|---|---|---|
| Cash & Equivalents | ₹1.28M | ₹116.94M |
| Total Current Assets | ₹1.82B | ₹519.73M |
| Total Current Liabilities | ₹412.69M | ₹205.60M |
| Long-Term Debt | ₹1.23B | ₹296.36M |
| Total Shareholders Equity | ₹1.03B | ₹2.48B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | N/A | ₹411.30M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | WELCURE | GUJTHEM |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | WELCURE | GUJTHEM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 7,522,990 | 137,612 |
| Average Daily Volume (90 Day) | 3,381,856 | 213,338 |
| Shares Outstanding | 112.51M | 108.97M |
| Float Shares | 11.04M | 30.70M |
| % Held by Insiders | 0.88% | 0.72% |
| % Held by Institutions | 0.00% | 0.01% |
Dividend Analysis & Yield Comparison: Welcure Drugs vs Gujarat Themis
| Metric | WELCURE | GUJTHEM |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |